Local controllability and optimal control for a model of combined anticancer therapy with control delays
Pages: 195  216,
Issue 1,
February
2017
doi:10.3934/mbe.2017013 Abstract
References
Full text (567.2K)
Related Articles
Jerzy Klamka  Silesian University of Technology, Department of Automatic Control, Akademicka 16, 44101 Gliwice, Poland (email)
Helmut Maurer  University of Münster, Institute of Computational and Applied Mathematics, Einsteinstr. 62, 48149 Münster, Germany (email)
Andrzej Swierniak  Silesian University of Technology, Department of Automatic Control, kademicka 16, 44101 Gliwice, Poland (email)
1 
G. Bergers and D. Hanahan, Modes of resistance to antiangiogenic therapy, Nature Reviews Cancer, 8 (2008), 592603. 

2 
A. C. Billioux, U. Modlich and R, Bicknell, The Cancer Handbook: Angiogenesis, 2nd Edition, John Wiley & Sons, 2007. 

3 
R. F. Brammer, Controllability in linear autonomous systems with positive controllers, SIAM J. Control, 10 (1972), 339353. 

4 
C. Büskens, Optimierungsmethoden und Sensitivitätsanalyse Für Optimale Steuerprozesse mit Steuer und ZustandsBeschränkungen, PhD thesis, Institut für Numerische Mathematik, Universität Münster, Germany, 1998. 

5 
C. Büskens and H. Maurer, SQP methods for solving optimal control problems with control and state constraints: Adjoint variables, sensitivity analysis and real time control, J. Comput. Appl. Math., 120 (2000), 85108. 

6 
J. M. Collins, D. S. Zaharko, R. L. Dedrick and B. A. Chabner, Potential roles for preclinical pharmacology in phase I clinical trials, Cancer Treat. Rep., 70 (1986), 7380. 

7 
V. T. Devita and J. Folkman, Cancer: Principles and Practice of Oncology, 6th edition, Lippincott Williams & Wilkins Publishers, 2001. 

8 
M. Dolbniak and A. Swierniak, Comparison of simple models of periodic protocols for combined anticancer therapy, Computational and Mathematical Methods in Medicine, 2013 (2013), Article ID 567213, 11pp. 

9 
A. D'Onofrio and A. Gandolfi, Tumor eradication by antiangiogenic therapy: Analysis and extensions of the model by Hahnfeldt et al. (1999), Mathematical Biosciences, 191 (2004), 159184. 

10 
A. D'Onofrio and A. Gandolfi, A family of models of angiogenesis and antiangiogenesis anticancer therapy, Mathematical Medicine and Biology, 26 (2009), 6395. 

11 
A. D'Onofrio and A. Gandolfi, Chemotherapy of vascularised tumors: Role of vessel density and the effect of vascular "pruning", Journal of Theoretical Biology, 264 (2010), 253265. 

12 
A. D'Onofrio, U. Ledzewicz, H. Maurer and H. Schaettler, On optimal delivery of combination therapy for tumors, Math. Biosciences, 222 (2009), 1326. 

13 
A. Ergun, K. Camphausen and L. M. Wein, Optimal scheduling of radiotherapy and angiogenic inhibitors, Bulletin of Mathematical Biology, 65 (2003), 407424. 

14 
J. Folkman, Antiangiogenesis: New concept for therapy of solid tumors, Annals of Surgery, 175 (1972), 409416. 

15 
J. Folkman, Tumor angiogenesis therapeutic implications, New England Journal of Medicine, 285 (1971), 11821186. 

16 
R. Fourer, D. M. Gay and B. W. Kernighan, AMPL: A Modeling Language for Mathematical Programming, Duxbury Press, BrooksCole Publishing Company, 1993. 

17 
G. Gasparini, R. Longo, M. Fanelli and B. A. Teicher, Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions, Journal of Clinical Oncology, 23 (2005), 12951311. 

18 
L. Göllmann and H. Maurer, Theory and applications of optimal control problems with multiple timedelays, Special Issue on Computational Methods for Optimization and Control, J. of Industrial and Management Optimization, 10 (2014), 413441. 

19 
P. Hahnfeldt, D. Panigrahy, J. Folkman and L. Hlatky, Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy, Cancer Research, 59 (1999), 47704775. 

20 
D. Hanahan and R. A. Weinberg, Hallmarks of cancer: The next generation, Cell, 144 (2011), 646674. 

21 
R. S. Kerbel, Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents, BioEssays, 13 (1991), 3136. 

22 
M. Kimmel and A. Swierniak, Control theory approach to cancer chemotherapy: Benefiting from phase dependence and overcoming drug resistance, Tutorials in Mathematical Biosciences III: Cell Cycle, Proliferation, and Cancer (A. FriedmanEd.), Lecture Notes in Mathematics, Mathematical Biosciences Subseries, Springer, Heidelberg, 1872 (2006), 185221. 

23 
J. Klamka, Controllability of Dynamical Systems, Kluwer Academic Publishers, Dordrecht, the Netherlands, 1991. 

24 
J. Klamka, Constrained controllability of nonlinear systems, J. Math. Anal. Appl., 201 (1996), 365374. 

25 
U. Ledzewicz and H. Schaettler, Antiangiogenic therapy in cancer treatment as an optimal control problem, SIAM Journal on Control and Optimization, 46 (2007), 10521079. 

26 
U. Ledzewicz and H. Schaettler, Analysis of optimal controls for a mathematical model of tumor antiangiogenesis, Optimal Control Applications and Methods, 29 (2008), 4157. 

27 
U. Ledzewicz and H. Schaettler, Optimal and suboptimal protocols for a class of mathematical models of tumor antiangiogenesis, J. Theor. Biol., 252 (2008), 295312. 

28 
U. Ledzewicz and H. Schaettler, On the optimality of singular controls for a class of mathematical models for tumor antiangiogenesis, Discrete and Continuous Dynamical Systems, Series B, 11 (2009), 691715. 

29 
U. Ledzewicz, J. Marriott, H. Maurer, and H. Schaettler, Realizable protocols for optimal administration of drugs in mathematical models for antiangiogenic treatment, Mathematical Medicine and Biology, 27 (2010), 157179. 

30 
U. Ledzewicz, H. Maurer and H. Schaettler, Minimizing tumor volume for a mathematical model of antiangiogenesis with linear pharmacokinetics, in Recent Advances in Optimization and its Applications in Engineering, 267276, Springer, 2010. 

31 
U. Ledzewicz, H. Maurer and H. Schättler, Optimal and suboptimal protocols for a mathematical model for tumor antiangiogenesis in combination with chemotherapy, Mathematical Biosciences and Engineering, 8 (2011), 307323. 

32 
J. Ma and D. J. Waxman, Combination of antiangiogenesis with chemotherapy for more effective cancer treatment, Molecular Cancer Therapeutics, 7 (2008), 36703684. 

33 
H. Maurer, C. Büskens, J. H. R. Kim and C. Y. Kaya, Optimization methods for the verification of second order sufficient conditions for bangbang control, Optimal Control Appl. Meth., 26 (2005), 129156. 

34 
N. P. Osmolovskii and H. Maurer, Applications to Regular and BangBang Control: SecondOrder Necessary and Sufficient Optimality Conditions in Calculus of Variations and Optimal Control, SIAM Advances in Design and Control, Vol. DC 24, SIAM Publications, Philadelphia, 2012. 

35 
M. J. Piotrowska and U. Forys, Analysis of the Hopf bifurcation for the family of angiogenesis models, Journal of Mathematical Analysis and Applications, 382 (2011), 180203. 

36 
R. K. Sachcs, L. R. Hlatky and P. Hahnfeldt, Simple ODE models of tumor growth and antiangiogenic or radiation treatment, Math. Comput. Mod, 33 (2001), 12971305. 

37 
H. Schättler and U. Ledzewicz, Geometric Optimal Control. Theory, Methods and Examples, Springer, New York, 2012. 

38 
A. Swierniak, Direct and indirect control of cancer populations, Bulletin of the Polish Academy of Sciences: Technical Sciences, 56 (2008), 367378. 

39 
A. Swierniak, Modelling combined antiangiogenic and chemotherapies, in: Proc. 14th National Conf. Appl. Math. Biol Medicine, Leszno, 2008, 127133. 

40 
A. Swierniak, Comparison of six models of antiangiogenic therapy, Applicationes Mathematicae, 36 (2009), 333348. 

41 
A. Swierniak, A. d'Onofrio and A.Gandolfi, Control problems related to tumor angiogenesis, Proc. of the 32nd Annual Conference on IEEE Industrial Electronics (IECON '06), Paris, 677681, November 2006. 

42 
A. Swierniak and J. Klamka, Local controllability of models of combined anticancer therapy with delays in control, Math. Model. Nat. Phenom., 9 (2014), 216226. 

43 
L. S. Teng, K. T. Jin, K. F. He, H. H. Wang, J. Cao and D. C. Yu, Advances in combination of antiangiogenic agents targeting VEGFbinding and conventional chemotherapy and radiation for cancer treatment, Journal of the Chinese Medical Association, 73 (2010), 281288. 

44 
The Internet Drug Index, (2015), http://www.rxlist.com/avastindrug/clinicalpharmacology.html 

45 
US National Institutes of Health, Clinical Trials, (last updated June 2015), http://www.clinicaltrials.gov/ct2/show/NCT00520013 

46 
A. Wächter and L. T. Biegler, On the implementation of an interiorpoint filter linesearch algorithm for largescale nonlinear programming, Mathematical Programming, 106 (2006), 2557. 

Go to top
